12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Egrifta tesamorelin regulatory update

Theratechnologies said Health Canada accepted for review an NDS for Egrifta tesamorelin to treat excess abdominal fat in HIV-infected patients with lipodystrophy. The NDS was submitted in June. The analog...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >